221 related articles for article (PubMed ID: 19321295)
21. In vitro and experimental therapeutic studies of the calcium channel blocker bepridil: detection of viable Leishmania (L.) chagasi by real-time PCR.
Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
Exp Parasitol; 2011 Jun; 128(2):111-5. PubMed ID: 21354141
[TBL] [Abstract][Full Text] [Related]
22. Activity of Cuban propolis extracts on Leishmania amazonensis and Trichomonas vaginalis.
Monzote Fidalgo L; Sariego Ramos I; García Parra M; Cuesta-Rubio O; Márquez Hernández I; Campo Fernández M; Piccinelli AL; Rastrelli L
Nat Prod Commun; 2011 Jul; 6(7):973-6. PubMed ID: 21834236
[TBL] [Abstract][Full Text] [Related]
23. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A
J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476
[TBL] [Abstract][Full Text] [Related]
24. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
25. Activity of physalins purified from Physalis angulata in in vitro and in vivo models of cutaneous leishmaniasis.
Guimarães ET; Lima MS; Santos LA; Ribeiro IM; Tomassini TB; Ribeiro dos Santos R; dos Santos WL; Soares MB
J Antimicrob Chemother; 2009 Jul; 64(1):84-7. PubMed ID: 19454526
[TBL] [Abstract][Full Text] [Related]
26. Early infection with Leishmania major restrains pathogenic response to Leishmania amazonensis and parasite growth.
González-Lombana CZ; Santiago HC; Macedo JP; Seixas VA; Russo RC; Tafuri WL; Afonso LC; Vieira LQ
Acta Trop; 2008 Apr; 106(1):27-38. PubMed ID: 18313021
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Trypan: a diminazene based drug as antileishmanial agent.
Macharia JC; Bourdichon AJ; Gicheru MM
Acta Trop; 2004; 92(3):267-72. PubMed ID: 15533297
[TBL] [Abstract][Full Text] [Related]
28. Effect of Brazilian copaiba oils on Leishmania amazonensis.
Santos AO; Ueda-Nakamura T; Dias Filho BP; Veiga Junior VF; Pinto AC; Nakamura CV
J Ethnopharmacol; 2008 Nov; 120(2):204-8. PubMed ID: 18775772
[TBL] [Abstract][Full Text] [Related]
29. In vitro antileishmanial and antitrypanosomal activities of flavanones from Baccharis retusa DC. (Asteraceae).
Grecco Sdos S; Reimão JQ; Tempone AG; Sartorelli P; Cunha RL; Romoff P; Ferreira MJ; Fávero OA; Lago JH
Exp Parasitol; 2012 Feb; 130(2):141-5. PubMed ID: 22143090
[TBL] [Abstract][Full Text] [Related]
30. In vivo activity of perifosine against Leishmania amazonensis.
Cabrera-Serra MG; Valladares B; Piñero JE
Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
[TBL] [Abstract][Full Text] [Related]
31. Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis.
Santa-Rita RM; Henriques-Pons A; Barbosa HS; de Castro SL
J Antimicrob Chemother; 2004 Oct; 54(4):704-10. PubMed ID: 15329361
[TBL] [Abstract][Full Text] [Related]
32. Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
Reimão JQ; Scotti MT; Tempone AG
Bioorg Med Chem; 2010 Nov; 18(22):8044-53. PubMed ID: 20934347
[TBL] [Abstract][Full Text] [Related]
33. Antileishmanial activity and trypanothione reductase effects of terpenes from the Amazonian species Croton cajucara Benth (Euphorbiaceae).
Lima GS; Castro-Pinto DB; Machado GC; Maciel MA; Echevarria A
Phytomedicine; 2015 Nov; 22(12):1133-7. PubMed ID: 26547537
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-2-activated natural killer cells may have a direct role in the control of Leishmania (Leishmania) amazonensis promastigote and macrophage infection.
Aranha FC; Ribeiro U; Basse P; Corbett CE; Laurenti MD
Scand J Immunol; 2005 Oct; 62(4):334-41. PubMed ID: 16253120
[TBL] [Abstract][Full Text] [Related]
35. Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages.
Prina E; Lang T; Glaichenhaus N; Antoine JC
J Immunol; 1996 Jun; 156(11):4318-27. PubMed ID: 8666803
[TBL] [Abstract][Full Text] [Related]
36. In vitro activities of thiadiazine derivatives against Leishmania amazonensis.
Monzote L; Montalvo AM; Fonseca L; Pérez R; Suárez M; Rodríguez H
Arzneimittelforschung; 2005; 55(4):232-8. PubMed ID: 15901047
[TBL] [Abstract][Full Text] [Related]
37. In vitro leishmanicidal activity of N-dodecyl-1,2-ethanediamine.
Silva AL; Adade CM; Shoyama FM; Neto CP; Padrón TS; de Almeida MV; Rezende CA; Silva CV; Souza MA
Biomed Pharmacother; 2012 Apr; 66(3):180-6. PubMed ID: 22440898
[TBL] [Abstract][Full Text] [Related]
38. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine.
Tempone AG; Perez D; Rath S; Vilarinho AL; Mortara RA; de Andrade HF
J Antimicrob Chemother; 2004 Jul; 54(1):60-8. PubMed ID: 15163652
[TBL] [Abstract][Full Text] [Related]
39. Quassin alters the immunological patterns of murine macrophages through generation of nitric oxide to exert antileishmanial activity.
Bhattacharjee S; Gupta G; Bhattacharya P; Mukherjee A; Mujumdar SB; Pal A; Majumdar S
J Antimicrob Chemother; 2009 Feb; 63(2):317-24. PubMed ID: 19036753
[TBL] [Abstract][Full Text] [Related]
40. In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis.
Garnier T; Brown MB; Lawrence MJ; Croft SL
J Pharm Pharmacol; 2006 Aug; 58(8):1043-54. PubMed ID: 16872550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
